B-cell receptor specific for Rabies virus glycoprotein (G) epitopes (BCR-RVG)

B-cell receptors (BCRs) specific for rabies virus glycoprotein (G) epitopes are specialized membrane-bound immunoglobulins located on the surface of B lymphocytes. These receptors are responsible for the direct recognition of the rabies virus G protein, which is the primary protein involved in viral attachment and entry into host cells (PubMed: 28931618). Upon binding to specific antigenic sites on the G protein, such as Site I, II, or III, the BCR triggers intracellular signaling cascades that result in B-cell activation, clonal expansion, and differentiation into memory B cells or plasma cells (PubMed: 31434738). This interaction is the cornerstone of active immunization, where rabies vaccines provide the antigen to stimulate these specific BCRs to produce protective neutralizing antibodies (WHO, 2018). Furthermore, the study of these BCRs allows for the development of recombinant monoclonal antibodies used in post-exposure prophylaxis to provide immediate passive immunity against the virus (PubMed: 30249823). Understanding the repertoire of these BCRs is essential for developing next-generation vaccines and monoclonal antibody therapies that can provide broader protection against various lyssaviruses (PubMed: 30249823). Therapeutic interventions, such as post-exposure prophylaxis (PEP), rely on the activation of these BCRs through vaccination or the administration of antibodies derived from them to prevent the virus from reaching the central nervous system (CDC, 2022).

Other names

Rabies virus G protein-specific B-cell receptorAnti-RVG BCRRabies glycoprotein-specific immunoglobulinAnti-rabies G protein B-cell receptor

Antigenic epitopes on the rabies virus glycoprotein bind to the B-cell receptor, triggering signal transduction through the CD79A/CD79B complex that leads to B-cell activation, clonal expansion, and the secretion of virus-neutralizing antibodies (PubMed: 31434738).